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Abstract
Nowadays, kidney tumor diagnosis benefits from large and highly accurate imagistic 
methods. A new imagistic method is contrast-enhanced ultrasound (CEUS) that accurately 
depicts the circulatory pattern of tumors. In kidney pathology, any mass or even capsular 
deformation depicted by B mode ultrasound represents an indication for CEUS. The kid-
ney is completely and uniformly vascularized. In cystic tumors, there is a lack of contrast 
loading. In “impure” cystic masses (Bosnian 3 and 4), CEUS reveals vascularized septa 
and walls. In malignant tumors, accelerated and heterogeneous loading of contrast agent 
is observed in arterial phase followed by early, inhomogeneous washout of the contrast 
agent compared to normal renal parenchyma. In the abscesses, the appearance is the early 
loading of the walls associated with moderate hyperemia of the normal circulatory bed. 
This chapter details the CEUS in kidney tumor pathology, emphasizing the accurate infor-
mation for the circulatory pattern of renal masses. It requires correlations with clinical 
data and information provided by other imaging explorations to make a final diagnosis.
Keywords: contrast-enhanced ultrasonography, Doppler ultrasonography,  
kidney tumors, kidney cysts, kidney abscesses
1. Introduction
Ultrasonography (US) is a diagnostic method based on the transmission and reception 
of ultrasounds in biological media, being frequently used in the “native” version with-
out added procedures. It is the most widely available imaging method. In recent years, 
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“conventional” ultrasound was optimized by numerous procedures, including those using 
“contrast agents.” It consists of intravenous administration of specific substances in order to 
improve the diagnostic information. The technique is called “contrast-enhanced ultrasound” 
(CEUS). It allows simultaneously visualization of the flows from the large vessels and from 
the microcirculation [1]. CEUS is independent of the characteristics of blood column move-
ment (velocity and angle of incidence of the ultrasound beam), being more sensitive than 
the Doppler technique. It permits the study of capillary circulation and detection of blood 
extravasations.
The CEUS method was first used for hepatic tumor pathology, but also for abdominal emer-
gencies (detection of infarct or parenchymal dilacerations). The indication of CEUS has 
evolved and expanded rapidly in recent years, with the development of new contrast agents 
as well as the identification of new directions called “clinical applications” [2]. In urology, 
CEUS may have clinical implications with diagnostic values added to the detection and char-
acterization of focal and diffuse renal, prostatic, testicular, and bladder lesions.
2. Principles
Ultrasound contrast agents are gas-filled microbubbles and are used clinically as blood 
pool tracers to significantly enhance the acoustic backscatter from blood. Definity (Lantheus 
Medical Imaging, North Billerica, MA, USA) and SonoVue (Bracco S.P.A., Milan, Italy) are 
two clinically licensed ultrasound contrast agents. MicroMarker (targeted and untargeted) 
(Bracco, Geneva, Switzerland; VisualSonics, Toronto, ON, Canada) is marketed as a preclini-
cal UCA for contrast enhancement and molecular imaging in small animals. The microbub-
bles are made up of a lipid coating and a gaseous content (sulfur hexafluoride). The substance 
has a much lower solubility than air, which gives it good blood balance [3]. The diameter of 
the microbubbles is similar to that of the red blood cells (7 microns), which allow the pas-
sage of the contrast agent through the pulmonary and peripheral capillary circulation with-
out any impediment. One of the main physic principles relies on the compressibility of the 
gases exposed to the pressure of an ultrasound beam. Microbubbles generate (through the 
mechanism called “non-linear vibration”) harmonic echoes (higher frequency multiples) that 
are recorded by the transducer. This behavior is significantly different from that of tissues. 
Ultrasound devices use ultrasound emissions to cancel the tissue signals and to accentuate 
the microbubble signals.
After intravenously administration of the contrast agent, an increased intensity signal com-
ing from the vessels is depicted on the ultrasound screen. This enhanced signal can be 
evaluated in the gray scale, in the color-coded modes or in the hybrid mode (the combina-
tion of the two). The CEUS technique has a dynamic character, being possible a continuous 
tracking of the contrast agent through a region of interest (ROI). In the case of the kidney, 
the contrast agent is initially visualized in the renal artery, progressing to the sinus, the 
renal cortical, and after a delay of several seconds to the renal medulla. The first 30–40 s 
(sec) postinjection is appropriate for the arterial phase and then 30–40 s for the venous 
phase [4] (Figure 1).
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The CEUS examination might be focused on a region of interest (ROI). The operator might 
analyze this ROI in real time, during the examination or through a dedicated soft that traces 
the time-intensity curves. The parameters obtained describe the vascular and temporal behav-
ior, depending on the different postadministration phases (<30–40 sec = arterial time; >30–
40 sec = venous time). The time-intensity curve (TIC) represents a quantitative analysis of the 
variability of the mean intensity within the selected sample over a period of time (Figure 2). 
They can be postprocessed on any video clip saved during CEUS [5].
Other qualitative useful information is represented by: the intensity of fill-in with contrast 
agent, the sense of fill-in, the fill-in pattern, the degree of wash-out of the contrast agent, the 
sense of wash-out, and the pattern of wash-out [6]. The evaluation of the lesions of interest is 
carried out as compared to the normal parenchyma.
Figure 1. CEUS evaluation of the kidney in very short time, there is a replenishment with microbubbles of cortex 
(periphery), cortex (columns), and the medulla.
Figure 2. Representation of time-intensity transit curves. A sample area mounted in a specific area considered “target.” 
Special software is representing the characteristics of perfusion.
3. Equipment
For CEUS technique, the ultrasound device must be capable of functioning in harmonic mode 
and benefit from the acoustic power adjustment. The transducers, similar to those currently 
used for B and Doppler mode examinations, differ in the ability to operate in contrast mode. 
The harmonic mode allows a real and effective discrimination of the echoes from the blood 
column to those from the tissues. The acoustic power regulation is set to a value of 0.09–0.11, 
which leads to the generation of harmonic echoes at the microbubble level, minimizing the 
harmonic echoes at the tissue level and the artifacts.
4. The examination technique
Prior to the examination, a peripheral vein (preferably the antecubital vein) is catheterized 
with a 20–22 Gauge needle. The examination methodology goes through the following steps: 
gray scale (for ROI detection), Doppler technique (for circulatory specificity assessment), and 
contrast media assessment (for ROI characterization).
The patient’s position is adapted for examination of the organ of interest. For retroperitoneal 
organs, it is recommended that the patient adopts a shallow breath to facilitate the mainte-
nance of the area of interest in the ultrasound examination plan.
After activating the contrast mode, the following settings of the ultrasound equipment must 
be done: the “Focus” position below the region of interest, the mechanical index at 0.09–0.11, 
and reduce “Gain” function.
The injection of the contrast agent (at an average dose of 2.4 ml) is followed by 10 ml of saline 
solution is bolus. At the time of injection, the ultrasound timer and record videos are started. 
The region of interest is dynamically tracked for up to 5 min postinjection. Theoretically, a 
second injection can be made immediately, although this is rarely necessary in clinical prac-
tice [7].
The quality of the CEUS image is limited, as in the case of the B mode ultrasound, by the 
localization of the region of interest, the presence of the intestinal gas or bone margins, and 
the patient weight [7].
For kidney CEUS examination, the literature proposed various contrast phase terminologies. 
One is similar to the terminology used by multiphase contrast-enhanced computer tomogra-
phy (CE-CT) and magnetic resonance imaging (MRI) [8]. This terminology uses three phases: 
corticomedullary (enhancing cortex with medullary pyramids not yet perfused, approxi-
mately 15–30 s after contrast agent injection), nephrographic (homogenously enhancing renal 
parenchyma, approximately 30–70 s postinjection), and delayed (>70 s postinjection) [8]. 
Other groups used the following terminology: arterial phase <30 s postinjection and delayed 
phase 30–90 s postinjection [9]. Other authors proposed other terminologies: cortical (8–35 s 
after injection), corticomedullary (36–120 s), and delayed (>120 s) [10].
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5. Precautions
The sulfur hexafluoride, the gaze part of the contrast agent is inert, nontoxic, with biocompat-
ible membranes and easily eliminated by breathing. The metabolism of the membranes cover-
ing the microbubbles is done in the liver. These features make CEUS exploration independent 
of renal or thyroid functions, being an alternative to computer tomography in cases of renal 
failure or patients with history of thyrotoxicosis.
Very rare side effects are possible due to the interaction of ultrasound with microbubbles. 
These interactions may be mechanical or chemical. Mechanical features include bubble 
expansion and capillary rupture. Transient hyperthermia during bubbles recovering after 
expansion can generate free radicals. The precipitating factor for these reactions is the use 
of a mechanical index of about 0.4 [11]. Anaphylactic reactions were reported in 0.002% of 
examinations [12, 13].
6. Contraindications
CEUS contraindications are: severe coronary artery disease and pulmonary hypertension, 
unstable ischemic heart disease, age <18 years, and pregnancy [14]. No renal side effects have 
been reported so far after using CEUS.
7. CEUS in renal pseudo-tumors
Renal pseudotumors refer to persistent fetal lobulation, dromedary hump, and hypertrophied 
column of Bertin. These mass-like lesions are frequently detected on conventional ultrasound. 
The characteristic features are: location between overlapping portions of two renal sinus 
systems, clear demarcation from the renal sinus, size <3 cm, similar echogenicity to renal 
parenchyma, and lesions being bordered by a junctional parenchyma line; the Doppler mode 
demonstrates the regular, branch-like blood flow in the lesion [15].
There are, however, a number of situations in which their diagnosis is difficult—they may 
be miss-interpreted as kidney tumors through 2D gray scale techniques. This confounding is 
found in the following circumstances: modified echogenicity compared to the parenchymal 
environment, infiltrative tumor formations (metastases and lymphomas) [16], abnormal vas-
cular tracts [17], and obese or noncooperative patients (Figure 3).
As CEUS is able to depict the microcirculation, this procedure could make the differential 
diagnosis between a pseudotumor and a solid mass. The vascular pattern of the “pseudo-
tumors” is similar to adjacent parenchyma [18] (Figures 4 and 5). The accuracy of CEUS is 
similar to contrast-enhanced computer tomography (CE-CT) or magnetic resonance imaging 
(MRI) for the depiction of a normal vascular pattern in a pseudotumor mass [18].
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Figure 5. (a–c) Pseudotumor of the left kidney. In gray scale ultrasonography (a), there is a suspicion of a tumor in the 
middle of the organ. In Doppler color mode (b), there is a small vessel in the suspected tumor, insufficient for an accurate 
diagnosis. In CEUS focused on the middle of the kidney, there is no specific pattern for neoplasia.
Figure 3. (a and b) Pseudotumor of the left kidney. In the middle part of the kidney, there is an area of parenchyma with 
hypoechoic and heterogeneous pattern suggesting a tumor. The aspect is uncertain and needs additional data especially 
from the vascular point of view.
Figure 4. (a and b) Pseudotumor of the left kidney (same case as previous). Evaluation with microbubbles demonstrates 
no tumor in the middle of the kidney. This is a proof of how useful can be CEUS in suspicion of tumors of the kidney.
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8. CEUS for solid renal lesions
For solid renal masses, revealed by mode B ultrasonography, the differentiation between 
benign and malignant lesions is very important. The most frequent malignant lesion is renal 
cell carcinoma (RCC). Angiomyolipoma (AML) and oncocytoma are renal benign lesions [19]. 
The vascular pattern is a major criterion of differentiation and might be done with CEUS. A 
different vascular behavior of the renal mass compared with the adjacent parenchyma is 
specific for a tumor lesion and might be suggestive for malignancy [20]. CEUS has a higher 
accuracy than Doppler technique for renal cancer detection (100% compared to 71%) [21].
Tumor thrombus in the renal vein is a parenchymal structure with similar vascularization as 
the origin tumor. CEUS identifies the arterial vessels inside this parenchymal structure devel-
oped in the renal vein for the identification of the tumor’s nature due to the presence of arte-
rial time within the thrombus of the vascular signal (Figure 6). However, an emphasis on this 
character depicted in the renal vein regions of interest requires an experienced operator [11].
9. Renal cell carcinoma (RCC)
The clear cell renal cell carcinoma (ccRCC) is the most frequent common variant of renal 
cancer. Histologically is characterized by numerous thin-walled blood vessels with rich blood 
flow. The frequent morphological features correspond to intratumoral necrosis, hemorrhage, 
and calcifications [22]. In ultrasound B mode, the small tumors are often hyperechoic, cor-
responding to the thin-walled blood vessels with rich blood flow and can mimic angiomyo-
lipoma (Figure 7) [8]. Larger tumors are hypoechoic and exophytic, with central anechoic 
necrosis (Figure 8) [8].
Figure 6. Malignant thrombus in inferior vena cava. Sagital evaluation of the retroperitoneal space with representation 
of inferior vena cava and a large parenchymal structure in the vessel. The aspect is typical for a thrombus. In the presence 
of a kidney tumor, the aspect suggests a vascular invasion.
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The accuracy of CEUS to predict malignancy was intensively studied, but the results were not 
similar among authors. These confounding results are due in part to different terminology 
regarding the arterial and delayed phases, in part due to different contrast agents, and in part 
due to different features corresponding to natural development of the tumor (different CEUS 
characteristics depending on size) [8]. Reviewing the literature, ccRCC shows on CEUS the fol-
lowing vascular pattern: early hyperenhancement compared no normal adjacent parenchyma, 
wash-out on delayed phase, and perilesional enhancement, rim-like, corresponding to a pseu-
docapsule. There is also a heterogeneous enhancement, which increases with the lesion size [8].
A meta-analysis studied 11 comparable studies (including 567 malignant lesions and 313 
benign lesions) and found a sensitivity of 88% and a specificity of 80% for CEUS to differenti-
ate between malignant and benign renal tumors [23].
Figure 8. Renal cell carcinoma. Gray scale ultrasonography of the right kidney. At the lower pole, there is a round, well 
defined parenchymal tumor. The aspect is typical for a renal cell carcinoma.
Figure 7. Renal cell carcinoma. Gray scale ultrasonography of the right kidney. At the upper pole, there is a hypoechoic 
tumor, relatively well defined.
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The papillary renal cell carcinoma are described in B mode ultrasound as unilocular and 
hypoechoic. The CEUS features of this type of RCC are: hypoenhance to renal parenchyma 
throughout examination and homogeneous [8].
10. Angiomyolipoma
Typically, AMLs contain macroscopic fat and in B mode ultrasound, there are homoge-
neously echogenic. There are lipid-poor AMLs that correspond to isoechoic feature on B 
mode ultrasound. The CEUS reveals for AMLs the following vascular pattern: homogeneous, 
hypoenhanced compared to adjacent renal parenchyma (Figure 9). The contrast agent persists 
in delayed phases. This characteristic is very important in differential algorithm for RCC [8].
11. Oncocytoma
Oncocytoma are considered benign lesions. In B mode ultrasound, a hypoechoic central scar 
might be present, and color Doppler might show central radiating vessels (Figure 10) [8]. The 
differential diagnosis with chromophobe RCC of low malignant potential might be difficult. 
The vascular pattern depicted on CEUS was described differently in published case reports. It 
was documented a spoke wheel configuration of vessels on CEUS in an oncocytoma [20]. But 
other authors depicted an enhancement from periphery to center [8, 23]. The majority of the 
reports found hyperenhancement early compared with normal renal parenchyma and persis-
tent (greater delayed) compared to ccRCC [8, 23].
Figure 9. (a and b) Angiomyolipoma. CEUS (left) and gray scale ultrasonography (right). There is a tumor, round, well 
defined, and hypoechoic, with peripheral vascularity. The aspect suggests the presence of a neoplasia, but is not entirely 
typical for angiomyolipoma.
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12. Metastases and lymphoma
Imaging features suggestive for metastasis or lymphoma are: size <3 cm, lack of spherical shape, 
“infiltrative” growth, multiplicity, and bilaterality. There are no capsules or calcifications [8]. 
Figure 11. Renal lymphoma. CEUS evaluation (left) with an area of hypoenhancement at the upper pole; gray scale 
evaluation (right) with no signs of tumor. Vascular evaluation seems to be superior for the diagnostic than the 
morphometric pattern.
Figure 10. Oncocytoma. Round, parenchymal mass with enhancement of the peripheral vascular bed in the arterial time 
(Section 22).
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Few case reports depicted CEUS vascular pattern of renal metastasis, which are hypovascular 
on all phases [8]. Renal lymphoma was also described as hypovascular throughout renal per-
fusion after contrast agent administration on ultrasound (Figure 11) [8].
13. Cystic renal lesions
At imaging studies, approximately 10% of kidney cancers have a complex cystic appearance. 
Nonmalignant renal tumors may also have a complex appearance. This is most commonly 
due to the hemorrhage, infection, inflammation or ischemia. Differentiation between complex 
cysts requiring surgical treatment or monitoring is essential. The identification of vascularity 
in the solid area or septa of cystic lesions by CEUS simplifies the diagnosis of lesions with 
high malignancy potential [24].
The Bosniak classification differentiates five categories of renal cysts named I, II, IIf, III, and 
IV based on the imaging criteria (ultrasound and CT), being used for further clinical manage-
ment of the patient [8, 25].
First Bosniak category, called I, depicts thin walls of the cyst, without septa and sharp margins. 
There are no solid components or calcifications. No enhancement is depicted on CEUS. There 
is no malignancy potential (Figure 12) [8, 25].
Figure 12. (a and b) Renal cyst. CEUS evaluation (a); an gray scale evaluation (b). In CEUS (asterisc), the lack of vascular 
signal suggests an avascular lesion compatible with the diagnosis of cyst.
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Renal cysts from second category, II, are characterized by septa thinner than 1 mm, which 
might have fine calcifications. No contrast enhancement or very discrete enhancement is 
observed. The malignant potential is 0% [8, 25].
In the third category, called IIF, the cysts have multiple septa, minimally thickened walls, thin 
or thick calcifications. On CEUS, a discrete enhancement of the walls and septa is depicted. 
The malignant potential is 5%, and these lesions need regular monitoring for 6 months [8, 25].
Renal cysts from the fourth category, called III, present homogeneous of irregular thickening 
of the walls and/or septa and irregular calcifications. The CEUS examination reveals multiple 
contrast enhancing septa. The malignant potential is 50% [8, 25].
In the last category, called IV, the cysts present solid components together with homogeneous 
of irregular thickening of the walls and/or septa and irregular calcifications. The CEUS exami-
nation depicts multiple contrast enhancing septa and irregular contrast enhancing soft tissue 
components. These lesions are considered malignant [8, 25].
The accuracy of CEUS in differentiating renal cystic lesions as benign or malignant is similar 
to CE-CT [11]. The sensitivity of CEUS for depicting the vascular signal at the level of the 
cystic components (septa, walls, and nodules) is superior to CE-CT [26]. However, CEUS does 
not have the same sensitivity as CT in detecting calcifications, a confounding factor for the 
measurement of wall thickness and septum [27].
14. CEUS for monitoring renal interventions
CEUS is a very accurate method to depict blood extravasation after kidney surgery.
In the last years, CEUS became a useful tool for monitoring during and after radiofrequency 
ablations (RFA) and cryoablation (CA). The CEUS score system for monitoring after these 
interventions was proposed by Wink et al. [28] in which 0 = no enhancement, 1 = rim enhance-
ment, 2 = diffuse enhancement, 3 = localized enhancement, and 4 = no defect in enhancement. 
The accuracy of CEUS compared to CE-CT or MRI was lower at 3 months post-treatment, but 
similar to these procedures at 12 month after [29].
15. Future expectations and developments in the field of kidney 
CEUS
A better quantification of blood flow could be achieved using contrast enhanced three-
dimensional (3D) harmonic ultrasound imaging (HI) and subharmonic ultrasound imaging 
(SHI) [30]. In this preliminary study, 3D contrast-enhanced nonlinear ultrasound was able 
to quantify perfusion in vivo, in canine kidneys. Three-dimensional SHI resulted in better 
overall agreement with the reference standard than 3D HI did and was superior to previ-
ously reported 2D SHI results. Three-dimensional SHI outperformed the other methods for 
estimating blood perfusion because of the improved visualization of the complete perfused 
vascular networks [30]. This 3D technique based on CEUS proved an accurate examination for 
detecting renal transplant perfusion defects [31].
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Another future application is related to robotic-assisted partial nephrectomy, which has gained 
prominence recently, as this approach has a shorter learning curve and a shorter warm ischemia 
time as compared to laparoscopic partial nephrectomy [32]. CEUS is capable of dynamic evalu-
ation and quantification of microvasculature blood (capillary perfusion) in real time, without 
affecting renal function. When used in conjunction with a robotic ultrasound probe, CEUS can 
facilitate better visualization of renal vasculature and tumor and ultimately improving acumen 
and precision. CEUS is a valuable and a cost-effective tool for the identification of renal blood 
flow in robotic-assisted partial nephrectomy, especially with complex, challenging tumors [32].
16. Conclusions
The CEUS examination is an important progress for ultrasonography. The procedure depicts 
dynamic angio-perfusion. It is valuable in strengthening the diagnosis of renal cancer by evidenc-
ing neo-angiogenesis. It is useful in detecting tumor and nontumor circulatory abnormalities.
Acknowledgement
This work was supported by a grant of the Romanian Ministry of Research and Innovation, 
CCDI-UEFISCDI, project number PN-III-P1-1.2-PCCDI-2017-0056/3, within PNCDI III.
Author details
Lidia Ciobanu*, Attila Tamas Szora, Alexandru Florin Badea, Mihai Suciu and Radu Badea
*Address all correspondence to: ciobanulidia@yahoo.com
University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania
References
[1] Badea R, Ciobanu L. Contrast enhanced and Doppler ultrasonography in the characteriza-
tion of the microcirculation. Expectancies and performances. Medical Ultrasonography. 
2012;14(4):307-317
[2] Cosgrove D, Eckersley R. Contrast-enhanced ultrasound: Basic physics and technol-
ogy overview. In: Lencioni R, editor. Enhancing the Role of Ultrasound with Contrast 
Agents. Milan: Springer; 2006. pp. 3-14
[3] Kono Y, Mattrey RF. Ultrasound of the liver. Radiologic Clinics of North America. 2005; 
43(5):815-826
[4] Nilsson A. Contrast-enhanced ultrasound of the kidneys. European Radiology. 2004; 
14(Suppl 8):104-109
Harmonic Contrast-Enhanced Ultrasound (CEUS) of Kidney Tumors 13
[5] Cosgrove D, Lassau N. Imaging of perfusion using ultrasound. European Journal of 
Nuclear Medicine and Molecular Imaging. 2010;37(Suppl 1):S65-S85
[6] Tranquart F, Mercier L, Frinking P, Gaud E, Arditi M. Perfusion quantification in con-
trast-enhanced ultrasound (CEUS)—Ready for research projects and routine clinical use. 
Ultraschall in der Medizin. 2012;33(Suppl 1):S31-S38
[7] Setola SV, Catalano O, Sandomenico F, Siani A. Contrast-enhanced sonography of the 
kidney. Abdominal Imaging. 2007;32(1):21-28
[8] Gulati M, King KG, Gill IS, Pham V, Grant E, Duddalwar VA. CEUS of cystic and solid 
renal lesions. Abdominal Imaging. 2015;40(6):1982-1996
[9] Fan L, Lianfang D, Jinfang X, Yijin S, Ying W. Diagnostic efficacy of contrast-enhanced 
ultrasonography in solid renal parenchymal lesions with maximum diameters of 5 cm. 
Journal of Ultrasound in Medicine. 2008;27(6):875-885
[10] Xu ZF, Xu HX, Xie XY, Liu GJ, Zheng YL, Liang JY, Lu MD. Renal cell carcinoma: Real-
time contrast-enhanced ultrasound findings. Abdominal Imaging. 2010;35(6):750-756
[11] Piscaglia F, Nolsøe C, Dietrich CF, et al. The EFSUMB guidelines and recommendations 
on the clinical practice of contrast enhanced ultrasound (CEUS): Update 2011 on non-
hepatic applications. Ultraschall in der Medizin. 2012;33(1):33-59
[12] Piscaglia F, Bolondi L. Italian society for ultrasound in medicine and biology (SIUMB) 
study group on ultrasound contrast agents. The safety of Sonovue in abdominal applica-
tions: Retrospective analysis of 23188 investigations. Ultrasound in Medicine & Biology. 
2006;32(9):1369-1375
[13] Ter Haar G. Safety and bio-effects of ultrasound contrast agents. Medical & Biological 
Engineering & Computing. 2009;47(8):893-900
[14] Main ML, Goldman JH, Grayburn PA. Ultrasound contrast agents: Balancing safety ver-
sus efficacy. Expert Opinion on Drug Safety. 2009;8(1):49-56
[15] Leekam RN, Matzinger MA, Brunelle M, Grey RR, Grosman H. The sonography of renal 
columnar hypertrophy. Journal of Clinical Ultrasound. 1983;11(9):491-494
[16] Ascenti G, Zimbaro G, Mazziotti S, Gaeta M, Lamberto S, Scribano E. Contrast-enhanced 
power Doppler US in the diagnosis of renal pseudotumors. European Radiology. 
2001;11(12):2496-2499
[17] Robbin ML, Lockhart ME, Barr RG. Renal imaging with ultrasound contrast: Current 
status. Radiologic Clinics of North America. 2003;41(5):963-978
[18] Mazziotti S, Zimbaro F, Pandolfo A, Racchiusa S, Settineri N, Ascenti G. Usefulness of 
contrast-enhanced ultrasonography in the diagnosis of renal pseudotumors. Abdominal 
Imaging. 2010;35(2):241-245
[19] Ignee A, Straub B, Schuessler G, Dietrich CF. Contrast enhanced-ultrasound of renal 
masses. World Journal of Radiology. 2010;2(1):15-31
Kidney Cancer14
[20] Tamai H, Takiguchi Y, Oka M, et al. Contrast-enhanced ultrasonography in the diagnosis 
of solid renal tumors. Journal of Ultrasound in Medicine. 2005;24(12):1635-1640
[21] Dong XQ, Shen Y, Xu LW, Xu CM, Bi W, Wang XM. Contrast-enhanced ultrasound 
for detection and diagnosis of renal clear cell carcinoma. Chinese Medical Journal. 
2009;122(10):1179-1183
[22] Reese JH. Renal cell carcinoma. Current Opinion in Oncology. 1992;4(3):427-434
[23] Wang C, Yu C, Yang F, Yang G. Diagnostic accuracy of contrast-enhanced ultrasound for 
renal cell carcinoma: A meta-analysis. Tumor Biology. 2014;35(7):6343-6350
[24] Aoki S, Hattori R, Yamamoto T, Funahashi Y, Matsukawa Y, Gotoh M, Yamada Y, Honda 
N. Contrast-enhanced ultrasound using a time-intensity curve for the diagnosis of renal 
cell carcinoma. BJU International. 2011;108(3):349-354
[25] Rubenthaler J, Bogner F, Reiser M, Clevert DA. Contrast-enhanced ultrasound (CEUS) of 
the kidney by using the Bosniak classification. Ultraschall in der Medizin. 2016;37:234-252
[26] Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY. Assessment of cystic renal masses 
based on Bosniak classification: Comparison of CT and contrast-enhanced US. European 
Journal of Radiology. 2007;61(2):310-314
[27] Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: Comparison 
of CT and MR imaging by using the Bosniak classification system. Radiology. 2004; 
231(2):365-371
[28] Wink MH, Laguna MP, Lagerveld BW, de la Rosette JJ, Wijkstra H. Contrast-enhanced 
ultrasonography in the follow-up of cryoablation of renal tumours: A feasibility study. 
BJU International. 2007;99(6):1371-1375
[29] Barwari K, Wijkstra H, van Delden OM, de la Rosette JJ, Laguna MP. Contrast-enhanced 
ultrasound for the evaluation of the cryolesion after laparoscopic renal cryoablation: An 
initial report. Journal of Endourology. 2013;27(4):402-407
[30] Sridharan A, Eisenbrey JR, Liu JB, Machado P, Halldorsdottir VG, Dave JK, Zhao H, He Y, 
Park S, Dianis S, Wallace K, Thomenius KE, Forsberg F. Perfusion estimation using 
contrast-enhanced 3-dimensional subharmonic ultrasound imaging: An in vivo study. 
Investigative Radiology. 2013;48(9):654-660. DOI: 10.1097/RLI.0b013e3182925160
[31] Stenberg B, Chandler C, Wyrley-Birch H, Elliott ST. Post-operative 3-dimensional 
contrast-enhanced ultrasound (CEUS) versus Tc99m-DTPA in the detection of post-
surgical perfusion defects in kidney transplants—Preliminary findings. Ultraschall in 
der Medizin. 2014;35(3):273-278. DOI: 10.1055/s-0033-1355964
[32] Alenezi AN, Karim O. Role of intra-operative contrast-enhanced ultrasound (CEUS) in 
robotic-assisted nephron-sparing surgery. Journal of Robotic Surgery. 2015;9(1):1-10. 
DOI: 10.1007/s11701-015-0496-1
Harmonic Contrast-Enhanced Ultrasound (CEUS) of Kidney Tumors 15

